2026 has marked a period of strong recovery for biotech funding, with a majority of gains coming in the first half of the year. A spate of large, clinical-stage deals have backboned the recovery, with median seed rounds trending upward of $50 million in 2026, compared with $14 million in 2022. Series A rounds are typically double this size, ranging from $60 million to $92 million.
Leveraging SuperAnalyst, AlphaSense’s always-on agent, we surface the relevant trends and data driving funding trends across biotech with analyst and expert perspectives. These insights shed light on where funding is going, the challenges early startups face, the importance of serial pipeline success, and the macro impact on funding at scale.
Mapping the Biotech Rebound in 2026
Total year-to-date biopharma funding including venture raises, IPOs, and follow-ons measures $58.9 billion, up 52% year over year. Findings from SuperAnalyst pinpoint seed and Series A biotech funding rounds, surfacing valuable data to illustrate the dynamics between the two.
With a simple prompt in SuperAnalyst, we map early funding activity in biotech startups with a robust dashboard that compares key stats such as median size, geographic distribution, and disclosed amounts as shown below.
While seed rounds outnumber Series A almost two to one, Series A funds raise about three times the amount. Year to date, there have been 603 seed rounds and 334 Series A, with disclosed dollar totals of $2.6 billion and $8.06 billion, respectively. The two stages also draw on different geographies, with China accounting for 28% of Series A rounds, but only 10% of seed.
Source: SuperAnalyst from AlphaSense
Funding Challenges and Early-Stage Obstacles
Seed funding alone is rarely sufficient for therapeutics or medtech startups to achieve value-creating milestones. Series A rounds often supply the critical capital for preclinical studies, IND filings, and early clinical trials.
With a $300 billion patent cliff looming for legacy therapeutics, investors are far less forgiving of clinical delays or setbacks, according to broker research. As a result, capital is concentrated in assets that have cleared high-risk preclinical phases. This risk mitigation has made the environment considerably more challenging for early-stage ventures than even five years ago, rewarding teams capable of delivering late-stage clinical data to support their pipelines.
Recent broker research supports this trend, noting that AI-native biotech firms must demonstrate consistent, serial pipeline advancements paired with compressed development schedules to earn sustained investor confidence.
A challenging funding environment also creates headwinds to pipeline advancement. Some experts believe that Series A and B startups still lack the funds to move as fast as big companies:
I believe that we will see a lot of peptide products on the market in the coming years. I believe that it could be a problem for small start-ups or maybe Series A, Series B start-ups because these companies are still lacking funds to move fast with big companies. It's really important to understand the timelines and to stay in these timelines with your specific method and all the tech things around it.
Target Criteria
Broker research on 1,107 Series A-C healthcare rounds of $10 million or more, totaling $61.8 billion, found that VC money mostly went to AI-enabled drug discovery, precision immunology, and targeted drug delivery. The research renders a $500–$550 billion total addressable market (TAM) for opportunities across these priority themes.
High-quality startups are also seeing success in securing “megarounds” of $100 million or more. For instance, Coultreon Biopharma secured a $125 million Series A in late 2026 to advance autoimmune therapies into Phase 2 trials.
Valuation Tied to Data, Clinical, and Operational Execution
According to broker research, valuation premiums in 2026 are increasingly tied to proprietary data flywheels and clinical execution rather than just foundational AI platforms.
Companies that successfully bridge to Series A funding rounds often see significant valuation step-ups if they achieve proof-of-concept (PoC). Broker research pinpoints the PoC as a “big inflection point” for valuation and partnering. As an example, Afana Biotechnology reached a $283.4 million valuation following a $50 million Series A raise in November 2026.
Source: Screener in AlphaSense
From an operational and commercial lens, founders are increasingly expected to have tightened operational structures in place for bookkeeping, legal counsel, and fractional CFO support before seeking Series A funding in order to pass investor due diligence. Success at Series A also requires a clear patient value proposition and understanding of patient needs, including delivery methods and usability, rather than just technical milestones.
Surface the Intelligence Behind the Headlines
Despite macroeconomic headwinds and shifting investor appetite, seed and Series A funding rounds in biotech continue to grow, with a roughly half-trillion-dollar TAM earmarked for priority themes on the horizon.
With SuperAnalyst, we surface the criteria that early-stage biotech startups are winning with: clinical proof-of-concept, serial pipeline progress, and operational and commercial excellence.
Surface the intelligence behind the headlines today with SuperAnalyst, and discover the market and expert signals that are driving capital.





